- LL-37 has well-described innate-immune and antimicrobial biology.
- FDA highlights limited safety information and concerns relevant to compounded use.
RESEARCH REBEL • EVIDENCE DOSSIER
LL-37
PRECLINICAL DOMINANT • SAFETY SIGNALEndogenous cathelicidin antimicrobial peptide with extensive mechanistic biology but insufficient evidence to validate community infection protocols.
- A validated general human therapeutic regimen for community uses.
- Long-term systemic safety across proposed routes/formulations.
PUBLISHED PROTOCOL EVIDENCE
Study parameter ≠ universal protocol.
No general validated community-use protocol is established. Infection-related self-treatment claims are not substituted for diagnosis or susceptibility data.
Numerical study entries carry:PopulationRouteFormulationAmountFrequencyDurationEndpointSource
COMMUNITY EVIDENCE
Document it. Don't upgrade it.
Community sinus, biofilm and infection reports remain anecdotal; a claimed 'Herx' reaction is not treated as proof of efficacy.
Reported amount/rangeRouteFrequencyDurationGoalReported positivesReported negativesConcurrent compoundsSource + N
COMMUNITY-REPORTED • NOT CLINICALLY VALIDATED